Oncolytic Viruses in Cancer Treatment

Lawler, Sean E.; Speranza, Maria-Carmela; Cho, Choi Fong; Chiocca, E. Antonio

doi:10.1001/jamaoncol.2016.2064

Cited by 494 publications

(415 citation statements)

References 86 publications

Supporting

Mentioning

407

Contrasting

Unclassified

Order By: Relevance

“…36 Two phase I/II clinical trials using the MAGE-A3 oncolytic vaccination platform are underway. The first utilizes the oncolytic Maraba MG1-MAGEA3 vaccine, either alone or following Ad-MAGEA3, for the treatment of patients with advanced MAGE-A3-positive solid malignancies (NCT02285816).…”

Section: Discussionmentioning

confidence: 99%

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

et al. 2018

View full text Add to dashboard Cite

Multiple immunotherapeutics have been approved for cancer patients, however advanced solid tumors are frequently refractory to treatment. We evaluated the safety and immunogenicity of a vaccination approach with multimodal oncolytic potential in non-human primates (NHP) (Macaca fascicularis). Primates received a replication-deficient adenoviral prime, boosted by the oncolytic Maraba MG1 rhabdovirus. Both vectors expressed the human MAGE-A3. No severe adverse events were observed. Boosting with MG1-MAGEA3 induced an expansion of hMAGE-A3-specific CD4+ and CD8+ T-cells with the latter peaking at remarkable levels and persisting for several months. T-cells reacting against epitopes fully conserved between simian and human MAGE-A3 were identified. Humoral immunity was demonstrated by the detection of circulating MAGE-A3 antibodies. These preclinical data establish the capacity for the Ad:MG1 vaccination to engage multiple effector immune cell populations without causing significant toxicity in outbred NHPs. Clinical investigations utilizing this program for the treatment of MAGE-A3-positive solid malignancies are underway (NCT02285816, NCT02879760).

show abstract

Section: Discussionmentioning

confidence: 99%

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Preclinical models have demonstrated an anticancer activity against numerous types of cancer (84). Currently, several recombinant viruses, including adenovirus, herpes simplex virus, vaccinia virus, reovirus, Newcastle disease virus and Parvovirus are in late phase clinical trials.…”

Section: Discussionmentioning

confidence: 99%

Advances in the mechanisms of action of cancer-targeting oncolytic viruses (Review)

et al. 2018

View full text Add to dashboard Cite

Abstract. Cancer virotherapy mediated by oncolytic viruses (OV), has emerged as a novel and effective strategy in cancer therapeutics. Preclinical models have demonstrated anticancer activity against numerous types of cancer. Currently, a number of recombinant viruses are in late phase clinical trials, many of which have demonstrated promising results regarding the safety and reliability of the treatments, particularly when combined with standard antineoplastic therapies. In addition to molecular-targeted therapeutics, genetic engineering of the viruses allows functional complementation to chemotherapy or radiotherapy agents. Co-administration of chemotherapy or radiotherapy is imperative for an effective treatment regime. Additionally, these approaches may be used in combination with current treatments to assist in cancer management. The near future may reveal whether this renewed interest in oncological virotherapy will result in meaningful therapeutic effects in patients. The aim of the present review was to highlight how the knowledge of oncolytic viral specificity and cytotoxicity has advanced in recent years, with a view to discuss OV in clinical application and the future directions of this field.

show abstract

“…OVs also release cancer antigens causing an immune attack against the infected malignant cells [1]. Thus, OVs offer the attractive therapeutic combination of tumor-specific cell lysis together with immune stimulation, therefore acting as potential in situ tumor vaccines [4].…”

Section: Introductionmentioning

confidence: 99%

“…They can be readily combined with other agents [4]. A potential advantage of virotherapy is long-term disease control with a single dose [2].…”

Section: Introductionmentioning

confidence: 99%

“…A potential advantage of virotherapy is long-term disease control with a single dose [2]. The effectiveness of OVs has been demonstrated in many preclinical studies and recently a major breakthrough for the field in humans, was the US Food and Drug Administration approval of the oncolytic herpes virus talimogene laherparepvec in advanced melanoma [4].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Oncolytic Virotherapy and Multiple Myeloma

Hamed¹

2017

BJSTR

View full text Add to dashboard Cite

Oncolytic Viruses in Cancer Treatment

Abstract: Oncolytic viruses are an active area of clinical research. The ability of these agents to harness antitumor immunity appears to be key for their success. Combinatorial studies with immune checkpoint blockade have started and the results are awaited with great interest.

Cited by 494 publications

References 86 publications

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials

Advances in the mechanisms of action of cancer-targeting oncolytic viruses (Review)

Oncolytic Virotherapy and Multiple Myeloma

Contact Info

Product

Resources

About